I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in ..:
Rosario García-Vicuña
;
Sebastián C. Rodriguez-García
;
Francisco Abad-Santos
...
https://www.frontiersin.org/articles/10.3389/fmed.2022.819621/full. , 2022
Link:
https://doi.org/10.3389/fmed.2022.819621
RT Journal T1
Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:2992076d61d949fdb47177e7a9cfa933&Exemplar=1&LAN=DE A1 Rosario García-Vicuña A1 Sebastián C. Rodriguez-García A1 Francisco Abad-Santos A1 Azucena Bautista Hernández A1 Lucio García-Fraile A1 Ana Barrios Blandino A1 Angela Gutiérrez Liarte A1 Tamara Alonso-Pérez A1 Laura Cardeñoso A1 Aránzazu Alfranca A1 Gina Mejía-Abril A1 Jesús Sanz Sanz A1 Isidoro González-Alvaro PB Frontiers Media S.A. YR 2022 K1 COVID-19 K1 sarilumab K1 subcutaneous route K1 IL-6 K1 IL-6 receptor inhibitors K1 IL-6 blockade K1 Medicine (General) K1 R5-920 JF https://www.frontiersin.org/articles/10.3389/fmed.2022.819621/full LK http://dx.doi.org/https://doi.org/10.3389/fmed.2022.819621 DO https://doi.org/10.3389/fmed.2022.819621 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)